登录
Exploring Real-World Outcomes of First Line EGFR Inhibitor Use, Cetuximab Versus Panitumumab, in Patients with Left-Sided, RAS Wild-Type, Metastatic Colorectal Cancer [0.03%] 左半侧、RAS野生型转移性结直肠癌患者一线使用西妥昔单抗与帕尼单抗的现实世界疗效：一项倾向匹配队列研究
Jane McKenzie,Vanessa Wong,Shehara Mendis et al. Jane McKenzie et al.
Background: Epidermal growth factor receptor inhibitors (EGFRi), most commonly cetuximab and panitumumab, are first-line options for patients with left-sided, RAS wildtype (RASwt) metastatic colorectal cancer. Limited dat...
Clinical Impact of Sub-Clonal RAS/BRAF Alterations in Liquid Biopsies From Patients With Advanced or Metastatic CRC [0.03%] 液态活检中亚克隆型RAS/BRAF突变在晚期或转移性结直肠癌患者中的临床影响
Peter Gibbs,Khalid Abubaker,Danyi Wang et al. Peter Gibbs et al.
Introduction: Colorectal cancer (CRC), a global health concern, requires effective treatments. Anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies are used for RAS wild-type and BRAFV600 mutation-negat...
Treatment of Oligometastatic BRAFV600E Mutant Colorectal Cancer: Learning From a Clinical Case [0.03%] 寡转移BRAF V600E突变型结直肠癌的治疗：从一例临床病例分析中学习
Renato Maria Marsicano,Luca Boscolo Bielo,Elena Guerini Rocco et al. Renato Maria Marsicano et al.
Q33.32024 Case Reports Clinical colorectal cancer. 2025 Mar 25:S1533-0028(25)00030-1. DOI:10.1016/j.clcc.2025.03.003 2025
Prognostic Relevance of ctDNA RAS Mutation in Patients With Metastatic Colorectal Cancer Treated With Cetuximab [0.03%] 西妥昔单抗治疗转移性结直肠癌患者中ctDNA RAS突变的预后价值
Seong-Eun Kim,Ji Sung Lee,Sun Young Kim et al. Seong-Eun Kim et al.
Background: RAS mutations are important biomarkers for predicting the efficacy of anti-EGFR treatment in metastatic colorectal cancer (mCRC). The emergence of RAS mutations is a known resistance mechanism. This study aime...
Circulating Tumor DNA in Addition to Fecal Immunochemical Test in a Dual-Test Colorectal Cancer Screening Approach [0.03%] 联合粪便免疫化学检测的循环肿瘤DNA在结直肠癌筛查中的应用研究
Caroline L Kahn,Mathias M Petersen,Jakob Kleif et al. Caroline L Kahn et al.
Background: Early detection is paramount when reducing incidence and mortality of colorectal cancer (CRC). Current population-based screening programs primarily use fecal immunochemical test (FIT) to allocate individuals ...
Escalated Segmental and Modified Radiation Lobectomy Dosing for Yttrium-90 Radioembolization of Liver-Dominant Metastatic Colorectal Cancer: 10-year Outcomes [0.03%] 用于肝主导的转移性结直肠癌钇-90放射栓塞治疗的剂量升级分段及改良放疗剂量：10年结果
Andrew C Gordon,Saad Abu Zahra,Muhamad Serhal et al. Andrew C Gordon et al.
Purpose: This study evaluates the safety and efficacy of escalated-dosing Yttrium-90 transarterial radioembolization (TARE) for unresectable, unablatable metastatic colorectal cancer (mCRC) to the liver. ...
Number of Lymph Nodes Examined as a Prognosis Factor in Patients With Stage II or III Colon Cancer [0.03%] 检查淋巴结作为II期或III期结肠癌患者预后因素的数量
Hyunwook Kim,Lingjie Shen,Jeongseok Jeon et al. Hyunwook Kim et al.
Background: Lymph node (LN) examination is important for staging colorectal cancer. Examining < 12 LN has been associated with a poor prognosis. However, surgical and pathological advances have led to increase examined LN...
Treatment Adherence to Adjuvant Chemotherapy According to the New Standard 3-month CAPOX Regimen in High-risk Stage II and Stage III Colon Cancer: A Population-based Evaluation in The Netherlands [0.03%] 根据新的标准3个月CAPOX方案，高危II期和III期结肠癌患者辅助化疗的治疗依从性：来自荷兰的人群评估研究
Kim van den Berg,Felice N van Erning,Jacobus Wa Burger et al. Kim van den Berg et al.
Background: A 3-month adjuvant treatment regimen with capecitabine and oxaliplatin (CAPOX) for high-risk stage II (T4N0) and stage III (node-positive) colon cancer was implemented in the Netherlands in 2017. The IDEA tria...
A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1) [0.03%] 杜斯特利马布单药治疗未经治疗的II/III期dMMR/MSI-H局部晚期直肠癌患者的二期、单臂、开放标签研究(AZUR-1)
Andrea Cercek,Jean-Baptiste Bachet,Jaume Capdevila et al. Andrea Cercek et al.
Background: Colorectal cancer (CRC) had the second highest cancer mortality worldwide in 2020; nearly a third of CRCs were rectal cancers (RC). A recent study demonstrated that dostarlimab, an immune-checkpoint inhibitor,...
Does Extramural Vascular Invasion Predict Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer? [0.03%] 肠旁血管侵犯能否预测局部晚期直肠癌新辅助治疗的疗效？
Neal Bhutiani,Mahmoud Mg Yousef,Abdelrahman Mg Yousef et al. Neal Bhutiani et al.
Introduction: Extramural vascular invasion (EMVI) is associated with distant recurrence after treatment of locogionally advanced rectal adenocarcinomas (LARCs), but its use as a marker for response to neoadjuvant therapy ...